Loughton was due to host about 23,000 chips from early 2027, while Nscale is pursuing an IPO after announcing convertible financing.
The once-daily device adds a second ZILBRYSQ self-injection format for adults with anti-AChR-positive gMG, with availability expected in the first quarter of 2027.
Pure holdings remained at zero in the Oct. 16 snapshot, but the weekly post disclosed neither sale prices nor dollar proceeds.
An Oct. 15 filing puts the appointment's effective date at Oct. 14 and details cash and equity terms for the new finance chief.
Exiro Nickel takes over operations while Vale Base Metals retains 18.9 per cent and a multi-year concentrate offtake agreement.
The nonprescription apraclonidine drops are approved for people aged 12 and older, with a U.S. retail launch expected in the coming months.
The Oct. 15 petition asks to participate in the PUC case over transmission costs and interruptible service for large data centres.
Three configurations include a single-seat Rocket version, while Porsche's vision model previews a permanent platform above the 911.
Ryzumvi's expanded indication triggers a milestone payment, while U.S. commercial rights belong to Viatris.
Golden Summit drilling supports a smaller starter pit for a 2027 prefeasibility study; true widths remain undetermined.
Varonis holders would receive US$49.75 per share, with shareholder and regulatory approvals required before a first-half 2027 close.
Each C$0.30 unit would include a common share and half a warrant, with closing targeted for Oct. 21.
The LNG exporter expects its first power-unit order by year-end, with further deployment tied to customer commitments.
Cash earnouts tied to 2026 and 2027 earnings add to the base price for a grower supplying nearly all 69 shops in the Dutch pilot.
The Yukon infill interval also contains gold and silver, while Phase 2 drilling is due to finish Oct. 20.
The preliminary study relies on molybdenum credits, while the release gives no tungsten output target or revenue contribution.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The revision incorporates Vogtle construction experience, with a Dec. 28 effective date conditional on the NRC comment process.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The hormone-free IUD remains approved for three years, with an FDA decision on a duration extension expected in the second quarter of 2027.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The automaker will contribute RMB1 billion, while outside investors commit RMB625 million to MHX Technology under conditional subscription agreements.
Uruguay estimates a US$5.7B project cost, while Solaria's filing leaves its funding share and tenant contracts unspecified.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Langer Heinrich produced 1.00 million pounds in the September quarter, while unit production costs rose to US$61.6 a pound.
The proposed project debt awaits lender diligence and final documents as Phase 1 completion remains targeted for December 2026.
Myriad would issue 1,571,268 shares, while Green Shift would retain a 2 per cent royalty with a partial buyback right.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The Oct. 15 move leaves Curaleaf's national store count at 189, with a York grand opening celebration scheduled for Oct. 23.
Three brands will be dropped as global teams take over operations, with full annualized savings forecast for fiscal 2028.
The approval adds adults with high-grade, BCG-unresponsive disease ahead of the Jan. 6, 2027 review target.
Germany's Tübingen authority certified softgel manufacturing and primary packaging of softgels, oral liquids and dried cannabis flower.
